PKD Educational Series
Join our renowned experts as they discuss and share their experience in autosomal dominant polycystic kidney disease (ADPKD) management in this learning series.
Themes & Objectives
- Discover the most common manifestations of ADPKD and the role of genetic testing
- Reflect on the past, present, and future of ADPKD management
- Identify patients with ADPKD for whom tolvaptan may be appropriate
- Recognize the role of V2 receptor signaling pathways
Jordan Weinstein
Associate Professor of Medicine,
University of Toronto
Nephrologist,
St. Michael’s Hospital
Founder & Director,
UKidney.com
Toronto, ON
Daniel Bichet
Professor of Medecine, Pharmacology and Physiology,
l’Université de Montréal
Nephrologist, Hôpital du Sacré-Cœur de Montréal
Montréal, QC
Arlene Chapman
Professor of Medicine, Department of Medicine,
Section Chief, Nephrology, Department of Medicine,
Director of Clinical Resource Center, University of Chicago
Chicago, IL, USA
York Pei
Senior Scientist,
Toronto General Hospital Research Institute (TGHRI)
Professor of Medicine, University of Toronto
Nephrologist,
Toronto General Hospital, University Health Network
Toronto, ON
Vicente E. Torres
Director,
Mayo Clinic Translational Polycystic Kidney Disease (PKD) Center
Consultant,
Division of Nephrology & Hypertension, Department of Internal Medicine
Rochester, MN, USA
